Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
AYAytu BioPharma, Inc. logo

Aytu BioPharma, Inc. (AYTU)

NASDAQ Capital Market · Currency in USD
$1.94 ▲ +0.04 (+2.11%)
As of Oct 26, 1:18 PM ET. Market open.

Summary

Previous Close
$1.90
Open
$1.91
Day's Range
$1.91 – $1.98
52 Week Range
$1.80 – $3.07
Volume
10,377
Avg. Volume
31,198
Market Cap
$21.08M
Beta (5Y Monthly)
0.27
PE Ratio (TTM)
--
EPS (TTM)
-$1.16
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Aytu BioPharma, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
76
CEO
Joshua R. Disbrow

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.26 · Revenue est. $13.27M
DateEst.Actual
Sep 22, 2026-$0.29-$0.05Beat
May 13, 2026-$0.31-$0.53Miss
Feb 3, 2026-$0.26-$1.05Miss
Nov 13, 2025-$0.06-$0.08Miss
Sep 23, 2025-$0.02-$2.92Miss
May 14, 2025-$0.17$0.20Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on AYTU and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.